Johnson & Johnson (JNJ) Shares Bought by Alps Advisors Inc.

Alps Advisors Inc. boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 1,624.6% in the second quarter, HoldingsChannel reports. The firm owned 259,727 shares of the company’s stock after purchasing an additional 244,667 shares during the period. Alps Advisors Inc.’s holdings in Johnson & Johnson were worth $36,289,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. BlackRock Inc. grew its stake in Johnson & Johnson by 4.7% in the first quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock valued at $22,476,102,000 after acquiring an additional 7,853,141 shares during the period. Fisher Asset Management LLC grew its stake in Johnson & Johnson by 3.8% in the second quarter. Fisher Asset Management LLC now owns 13,118,604 shares of the company’s stock valued at $1,591,811,000 after acquiring an additional 478,982 shares during the period. Dimensional Fund Advisors LP grew its stake in Johnson & Johnson by 9.5% in the first quarter. Dimensional Fund Advisors LP now owns 7,552,034 shares of the company’s stock valued at $967,793,000 after acquiring an additional 654,350 shares during the period. The Manufacturers Life Insurance Company grew its stake in Johnson & Johnson by 11.0% in the first quarter. The Manufacturers Life Insurance Company now owns 7,080,648 shares of the company’s stock valued at $907,384,000 after acquiring an additional 702,986 shares during the period. Finally, Bank of Montreal Can grew its stake in Johnson & Johnson by 36.1% in the second quarter. Bank of Montreal Can now owns 6,910,459 shares of the company’s stock valued at $838,515,000 after acquiring an additional 1,833,622 shares during the period. Institutional investors and hedge funds own 66.60% of the company’s stock.

Shares of NYSE:JNJ opened at $145.30 on Friday. The company has a market cap of $382.50 billion, a P/E ratio of 19.90, a P/E/G ratio of 2.23 and a beta of 0.58. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.72. Johnson & Johnson has a 12-month low of $118.62 and a 12-month high of $148.32.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.03 by $0.02. The company had revenue of $20.35 billion for the quarter, compared to analysts’ expectations of $20.05 billion. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. Johnson & Johnson’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.90 earnings per share. As a group, research analysts predict that Johnson & Johnson will post 8.16 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Investors of record on Tuesday, November 27th will be given a dividend of $0.90 per share. The ex-dividend date is Monday, November 26th. This represents a $3.60 annualized dividend and a dividend yield of 2.48%. Johnson & Johnson’s payout ratio is 49.32%.

In other Johnson & Johnson news, COO Michael E. Sneed sold 29,000 shares of the business’s stock in a transaction on Monday, August 27th. The stock was sold at an average price of $134.80, for a total value of $3,909,200.00. Following the transaction, the chief operating officer now owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CAO Ronald A. Kapusta sold 7,899 shares of the business’s stock in a transaction on Friday, September 7th. The stock was sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the transaction, the chief accounting officer now directly owns 25,725 shares in the company, valued at approximately $3,528,955.50. The disclosure for this sale can be found here. 0.22% of the stock is owned by insiders.

A number of brokerages have commented on JNJ. Wells Fargo & Co reissued an “outperform” rating and issued a $160.00 price objective on shares of Johnson & Johnson in a research note on Friday, September 14th. Credit Suisse Group raised their price objective on Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a research note on Wednesday, October 17th. Citigroup raised their price objective on Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a research note on Monday, October 22nd. Raymond James raised their price objective on Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a research note on Wednesday, October 17th. Finally, HC Wainwright reissued a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday, October 17th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $142.54.

COPYRIGHT VIOLATION NOTICE: “Johnson & Johnson (JNJ) Shares Bought by Alps Advisors Inc.” was reported by WKRB News and is owned by of WKRB News. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.wkrb13.com/2018/11/09/johnson-johnson-jnj-shares-bought-by-alps-advisors-inc.html.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Return on Equity (ROE)

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply